Turgut Pharmaceuticals aims to create an international standards-compliant biotechnology infrastructure based on R&D in Turkey, and to develop, manufacture and market high-quality biotechnology products for Turkish and global markets. Turgut Group is one of the leading entrepreneur institutions of Turkish Pharmaceutical Industry with its experience of more than 50 years and solid financial structure. By incorporating Turkish Pharmaceutical Industry's leading companies, Turgut Group performed design, construction and management of notable and pioneering active substance and drug product manufacturing facilities in Turkey. The Group also manufactured and marketed wide range of pharmaceuticals through successful and long-standing collaborations with various global companies. Establishing the Biotechnology Group in early 2014 as part of a strategic decision, Turgut Pharmaceuticals redefined its priorities and main objectives, and concentrated its operations and investments in the field of biotechnology. In this framework, the company determined basic requirements for developing and manufacturing world-class biosimilar drugs by collaborating with domestic and international expert organizations, identified shortcomings by examining the biotechnology infrastructure in our country, and came up with a strategic plan based on tangible data that incorporates solutions to establish a sustainable biotechnology infrastructure as quickly as possible taking into account the conditions prevalent in our country and to develop and launch high-quality biosimilar monoclonal antibodies. The investment made by Turgut Pharmaceuticals in order to implement this strategy is one of the largest in the field of biotechnology in Turkey. This strategic plan covers three main fields of activity, as well as the establishment of a world-class biotechnology platform in Turkey. • R&D-Based Product Development • GMP Biotechnology Manufacturing Facility • Domestic and International Collaborations